Physician Views: What commercial impact for Eylea from the Protocol T study in diabetic macular oedema?

Physician Views: What commercial impact for Eylea from the Protocol T study in diabetic macular oedema?

Code: FW-20150404 | Published: Apr-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






It seems that controversy over the use of off-label Avastin as a much cheaper alternative to Lucentis for the treatment of various ophthalmic indications is never far from the surface.

A recent article published by the British Medical Journal claims that Novartis (which markets Lucentis in Europe) sought to block studies in the UK that were comparing the effectiveness of the two drugs for the treatment of wet age-related macular degeneration (AMD).

It is the US market, where Roche markets both Avastin and Lucentis (the latter is a fragment of the formers full antibody), where off-label use is more extensive, but the practice occurs across numerous global markets.

Lucentis is not the only approved AMD therapy impacted by the practice, although Regeneron Pharmaceuticals and Bayers Eylea has performed extremely well since launching in 2011. With approval of Lucentis and Eylea for the treatment of diabetic macular oedema (DME) having occurred last year, however, and with this indication expected to act as a key driver of growth for Eylea in particular, some emphasis is shifting to off-label Avastin use in the DME setting.

This is particularly pertinent for Regeneron and Bayer as data from the NIH-sponsored Protocol T study, which was published in February, appears to confirm Eylea as a notably superior therapy to both Lucentis and Avastin for the treatment of DME (ViewPoints: Protocol T could be the gift that keeps on giving for Regenerons Eylea).

Converting any clinical advantage to the commercial setting may prove challenging, however, given the significantly lower cost of Avastin, at around $50 for a single injection versus approximately $1950 per injection for Eylea.








To better ascertain the impact of the Protocol T study results on uptake of Eylea, FirstWord is this week polling both US and EU5-based ophthalmologists. Specifically we are asking them




- Which therapy (Lucentis, Eylea or Avastin) they expect to be using most frequently for the treatment of DME in five years time?
How significant a role do you think data from the NIH-sponsored Phase III Protocol T study will play in driving overall usage of Eylea for the treatment of DME?
- In the first-line setting, what level of overall switching (or alternative new start drug) from off-label Avastin to Eylea they expect to occur on the basis of data from the Protocol T study?
- Whether they expect this level of switching/alternative new start drug (i.e. Eylea in favour of off-label Avastin) to be more pronounced in DME patients with severe vision impairment?
- Whether they agree with the suggestion that the authors of the Protocol T study results have understated the benefit that Eylea demonstrates versus Lucentis and Avastin for the treatment of DME, possibly in deference to their belief that the performance of Avastin looks good enough given its much lower price?





Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients